Deutsche Bank AG Boosts Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Deutsche Bank AG raised its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 75.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,093 shares of the company's stock after buying an additional 6,933 shares during the quarter. Deutsche Bank AG owned about 0.05% of Disc Medicine worth $1,020,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of IRON. Sterling Capital Management LLC grew its holdings in shares of Disc Medicine by 798.4% during the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after buying an additional 503 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after buying an additional 266 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Disc Medicine in the fourth quarter valued at about $235,000. Bayesian Capital Management LP purchased a new stake in shares of Disc Medicine in the fourth quarter valued at about $285,000. Finally, Teacher Retirement System of Texas grew its holdings in shares of Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock valued at $308,000 after purchasing an additional 396 shares during the period. Hedge funds and other institutional investors own 83.70% of the company's stock.

Insiders Place Their Bets

In related news, insider William Jacob Savage sold 6,677 shares of Disc Medicine stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $50.04, for a total value of $334,117.08. Following the transaction, the insider now directly owns 59,721 shares in the company, valued at $2,988,438.84. This trade represents a 10.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mona Ashiya sold 202,146 shares of Disc Medicine stock in a transaction on Monday, March 10th. The shares were sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the completion of the transaction, the director now owns 208,742 shares in the company, valued at approximately $11,332,603.18. This trade represents a 49.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 349,510 shares of company stock valued at $18,936,535. 4.24% of the stock is owned by corporate insiders.

Disc Medicine Trading Down 1.7%

NASDAQ:IRON traded down $0.76 during mid-day trading on Wednesday, hitting $45.12. The stock had a trading volume of 274,276 shares, compared to its average volume of 346,061. The stock has a 50-day simple moving average of $45.33 and a two-hundred day simple moving average of $54.39. The company has a market capitalization of $1.56 billion, a PE ratio of -11.34 and a beta of 0.77. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). Sell-side analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Analyst Ratings Changes

IRON has been the subject of a number of analyst reports. Scotiabank upped their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. Cantor Fitzgerald upped their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. Morgan Stanley reissued an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Friday, March 7th. TD Cowen assumed coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating for the company. Finally, BMO Capital Markets increased their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a research note on Monday, May 12th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $98.80.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.